专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004105684A3 COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS 审中-公开
标题翻译：加重疾病的组合治疗
公开(公告)号：WO2004105684A3
公开(公告)日：2008-12-11
申请号：PCT/US2004015346
申请日：2004-05-13
申请人： INTERMUNE INC , BLATT LAWRENCE M , SEIWERT SCOTT D , OZES OSMAN N
发明人： BLATT LAWRENCE M , SEIWERT SCOTT D , OZES OSMAN N
IPC分类号： A61K38/00 , A61K20060101 , A61K31/00 , C07K14/00
CPC分类号： A61K38/212 , A61K31/573 , A61K38/217 , A61K45/06 , A61K2300/00
摘要： The present invention provides methods of treating proliferative disorders, including angiogenesis-mediated disorders, cancer, and fibrotic disorders. In some embodiments, the methods involve administering a Type II interferon receptor agonist and a Type I interferon receptor agonist. In other embodiments, the methods involve administering a Type II interferon receptor agonist, a stress-activated protein kinase (SAPK) inhibitor, and a third therapeutic agent. In other embodiments, the methods involve administering a Type II interferon receptor agonist and a vascular endothelial growth factor (VEGF) antagonist. In other embodiments, the methods involve administering a VEGF antagonist and a SAPK inhibitor. The present invention further provides methods of treating fibrotic disorders. In some embodiments, the methods involve administering a Type I interferon receptor agonist, a Type II interferon receptor agonist; and a tumor necrosis factor (TNF) antagonist. In other embodiments, the methods involve administering a Type II interferon receptor agonist and a TNF antagonist. In other embodiments, the methods involve administering pirfenidone or a pirfenidone analog and a TNF antagonist. In other embodiments, the methods involve administering a Type II interferon receptor agonist and a transformining growth factor-beta (TGF-ß) antagonist. In other embodiments, the methods involve administering a SAPK inhibitor alone or in combination with a Type II interferon receptor agonist. In other embodiments, the methods involve administering N-acetyl cysteine (NAC) and a SAPK inhibitor. In other embodiments, the methods involve administering NAC and a Type II interferon receptor agonist.
摘要翻译：本发明提供了治疗增殖性疾病，包括血管发生介导的病症，癌症和纤维化病症的方法。在一些实施方案中，所述方法包括施用II型干扰素受体激动剂和I型干扰素受体激动剂。在其它实施方案中，所述方法包括施用II型干扰素受体激动剂，应激激活蛋白激酶（SAPK）抑制剂和第三治疗剂。在其它实施方案中，所述方法包括施用II型干扰素受体激动剂和血管内皮生长因子（VEGF）拮抗剂。在其它实施方案中，所述方法包括施用VEGF拮抗剂和SAPK抑制剂。本发明还提供治疗纤维化疾病的方法。在一些实施方案中，所述方法包括施用I型干扰素受体激动剂，II型干扰素受体激动剂; 和肿瘤坏死因子（TNF）拮抗剂。在其它实施方案中，所述方法包括施用II型干扰素受体激动剂和TNF拮抗剂。在其它实施方案中，所述方法包括施用吡非尼酮或吡非尼酮类似物和TNF拮抗剂。在其它实施方案中，所述方法包括施用II型干扰素受体激动剂和变应性生长因子-β（TGF-β）拮抗剂。在其它实施方案中，所述方法包括单独或与II型干扰素受体激动剂组合施用SAPK抑制剂。在其它实施方案中，所述方法包括给予N-乙酰半胱氨酸（NAC）和SAPK抑制剂。在其它实施方案中，所述方法包括施用NAC和II型干扰素受体激动剂。

2. 发明申请

WO2005040758A3 USE OF PIRFENIDONE IN THERAPEUTIC REGIMENS 审中-公开
标题翻译：吡蚜酮在治疗方案中的应用
公开(公告)号：WO2005040758A3
公开(公告)日：2005-09-29
申请号：PCT/US2004035390
申请日：2004-10-21
申请人： INTERMUNE INC , OZES OSMAN N , BLATT LAWRENCE M , SEIWERT SCOTT D
发明人： OZES OSMAN N , BLATT LAWRENCE M , SEIWERT SCOTT D
IPC分类号： A61K31/4412 , G01N33/50 , A61K31/445
CPC分类号： A61K31/47 , A61K31/4412 , A61K38/212 , A61K38/217 , A61K45/06 , G01N33/5091 , A61K2300/00
摘要： The present invention provides methods for treating a disorder, and methods for inhibiting a stress-activated protein kinase (SAPK) in a cell in an individual, the methods generally involving administering to an individual in need thereof an effective amount of pirfenidone or a pirfenidone analog; comparing a post-treatment SAPK activity level in a biological sample from the individual with a pre-treatment SAPK activity level; and adjusting the dose of the pirfenidone or pirfenidone analog based on the results of the comparison step. The present invention provides methods for treating a disorder, and methods for inhibiting a SAPK in a cell in an individual, the methods generally involving administering to an individual in need thereof an effective amount of pirfenidone or a pirfenidone analog; comparing a second post-treatment SAPK activity level in a biological sample from the individual with a first post-treatment SAPK activity level; and adjusting the dose of the pirfenidone or pirfenidone analog based on the results of the comparison step.
摘要翻译：本发明提供了治疗病症的方法，以及用于抑制个体细胞中应激活化蛋白激酶（SAPK）的方法，所述方法通常包括给予有需要的个体有效量的吡非尼酮或吡非尼酮类似物 ; 将来自个体的生物样品中的治疗后SAPK活性水平与治疗前SAPK活性水平进行比较; 以及基于比较步骤的结果调整吡非尼酮或吡非尼酮类似物的剂量。本发明提供治疗病症的方法和抑制个体细胞中SAPK的方法，所述方法通常包括给予有需要的个体有效量的吡非尼酮或吡非尼酮类似物; 将来自个体的生物样品中的第二治疗后SAPK活性水平与第一治疗后SAPK活性水平进行比较; 以及基于比较步骤的结果调整吡非尼酮或吡非尼酮类似物的剂量。

3. 发明申请

WO2005110455A3 COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTION 审中-公开
标题翻译：用于治疗乙型肝炎病毒感染的组合治疗
公开(公告)号：WO2005110455A3
公开(公告)日：2007-12-21
申请号：PCT/US2005016353
申请日：2005-05-09
申请人： INTERMUNE INC , OZES OSMAN N , SEIWERT SCOTT D , BLATT LAWRENCE M
发明人： OZES OSMAN N , SEIWERT SCOTT D , BLATT LAWRENCE M
IPC分类号： A01N43/04 , A61K31/70 , A61K31/7056 , A61K38/05 , A61K38/19 , C07H19/00 , C07H21/00
CPC分类号： A61K38/212 , A61K31/7056 , A61K2300/00
摘要： The present invention provides methods of treating a viral infection, e.g., a hepatitis C virus (HCV) infection; methods of reducing the incidence of complications associated with HCV infection and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a viral infection, e.g., an HCV infection. The methods generally involve administering to the individual i) a stress-activated protein kinase inhibitor; and ii) a Type I interferon receptor agonist. The present invention provides a method of treating alcoholic liver disease, the method involving administering to an individual in need thereof an effective amount of a stress-activated protein kinase (SAPK) inhibitor, alone or in combination therapy. The present invention further provides methods for treating non-alcoholic steatohepatitis, the method generally involving administering to an individual in need thereof an effective amount of a SAPK inhibitor, alone or in combination therapy.
摘要翻译：本发明提供了治疗病毒感染例如丙型肝炎病毒（HCV）感染的方法; 降低HCV感染和肝硬化相关并发症发生率的方法; 以及在患有病毒感染（例如HCV感染）的患者中减少病毒载量或减少病毒清除时间或降低临床结果的发病率或死亡率的方法。所述方法通常涉及对个体施用i）应激活化蛋白激酶抑制剂; 和ii）I型干扰素受体激动剂。本发明提供一种治疗酒精性肝病的方法，所述方法包括单独给药或联合治疗给有需要的个体有效量的应激活化蛋白激酶（SAPK）抑制剂。本发明还提供了治疗非酒精性脂肪性肝炎的方法，所述方法通常涉及单独或联合治疗单独施用有效量的SAPK抑制剂的需要的个体。

4. 发明申请

WO2005040758A8 USE OF PIRFENIDONE IN THERAPEUTIC REGIMENS 审中-公开
公开(公告)号：WO2005040758A8
公开(公告)日：2005-06-30
申请号：PCT/US2004035390
申请日：2004-10-21
申请人： INTERMUNE INC , OZES OSMAN N , BLATT LAWRENCE M
发明人： OZES OSMAN N , BLATT LAWRENCE M
IPC分类号： A61K31/4412 , G01N33/50 , A61K31/445
CPC分类号： A61K31/47 , A61K31/4412 , A61K38/212 , A61K38/217 , A61K45/06 , G01N33/5091 , A61K2300/00
摘要： The present invention provides methods for treating a disorder, and methods for inhibiting a stress-activated protein kinase (SAPK) in a cell in an individual, the methods generally involving administering to an individual in need thereof an effective amount of pirfenidone or a pirfenidone analog; comparing a post-treatment SAPK activity level in a biological sample from the individual with a pre-treatment SAPK activity level; and adjusting the dose of the pirfenidone or pirfenidone analog based on the results of the comparison step. The present invention provides methods for treating a disorder, and methods for inhibiting a SAPK in a cell in an individual, the methods generally involving administering to an individual in need thereof an effective amount of pirfenidone or a pirfenidone analog; comparing a second post-treatment SAPK activity level in a biological sample from the individual with a first post-treatment SAPK activity level; and adjusting the dose of the pirfenidone or pirfenidone analog based on the results of the comparison step.

5. 发明申请

WO2005000227A2 METHODS OF TREATING TNF-MEDIATED DISORDERS 审中-公开
标题翻译：治疗TNF介导的疾病的方法
公开(公告)号：WO2005000227A2
公开(公告)日：2005-01-06
申请号：PCT/US2004017728
申请日：2004-06-03
申请人： INTERMUNE INC , OZES OSMAN N , BLATT LAWRENCE M
发明人： OZES OSMAN N , BLATT LAWRENCE M
IPC分类号： A61K20060101 , A61K31/44 , A61K38/00 , A61K38/16 , A61K39/00 , A61K39/395 , A61K39/40 , A61K39/42 , C07K16/00 , A61K
CPC分类号： A61K38/28 , A61K31/4412 , A61K38/1793 , A61K45/06 , A61K2300/00
摘要： The present invention provides methods of treating TNF-alpha-mediated disorders, the methods generally involving administering to an individual in need thereof effective amounts of pirfenidone or a pirfenidone analog and a second therapeutic agent that reduces TNF-alpha synthesis or that reduces TNF-alpha binding to a TNF receptor. The present invention further provides methods for treating non-alcoholic steatohepatitis, the method generally involving administering to an individual in need thereof an effective amount of pirfenidone. The present invention further provides methods of treating end-stage or advanced Type II diabetes, the methods generally involving administering to an individual in need thereof effective amounts of pirfenidone and insulin.
摘要翻译：本发明提供了治疗TNF-α介导的病症的方法，所述方法通常包括向有需要的个体施用有效量的吡非尼酮或吡非尼酮类似物和第二治疗剂，其减少TNF-α合成或减少TNF-α 结合TNF受体。本发明进一步提供治疗非酒精性脂肪性肝炎的方法，所述方法通常包括对有需要的个体施用有效量的吡非尼酮。本发明进一步提供了治疗终末期或晚期II型糖尿病的方法，所述方法通常包括向有需要的个体施用有效量的吡非尼酮和胰岛素。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式